๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer

โœ Scribed by L. Kayitalire; F. Thomas; T. Chevalier; C. Toussaint; T. Tursz; M. Spielmann

Publisher
Springer US
Year
1992
Tongue
English
Weight
384 KB
Volume
10
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Methotrexate, vinblastine, doxorubicin,
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group
โœ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 490 KB ๐Ÿ‘ 2 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp

Phase II study of ionidamine in patients
Phase II study of ionidamine in patients with metastatic breast cancer
โœ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer US ๐ŸŒ English โš– 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi